Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

This is some text inside of a div block.
This is some text inside of a div block.

Problem Tech Solves

Tech Brief

With 6 in 10 adults(1) managing a chronic condition, there is a pervasive need for efficient, scalable solutions that simplify self-management and enable improved outcomes. Despite the increased prevalence and demand for chronic care support, data show that 50% of those(2) with chronic conditions are not taking their medication as prescribed. There is a disconnect between the need for a connected care experience and the capabilities of available solutions - Welldoc is bridging these gaps to extend connected care and address complex combinations of the world’s most widespread conditions and comorbidities. Not only is Welldoc addressing an area of unmet need for a highly prevalent patient population, we are working to break down barriers to access and overcome the resourcing obstacles that exist in healthcare. With healthcare worker and physician shortages projected to outpace demand in the next 5-15 years(1, 2), there is an urgent need to adapt existing care models to compensate for the rising demand for care support. There are only about 8,000 endocrinologists in the US(3), which is indicative of the immensely limited access to chronic care specialists. By seamlessly integrating into existing health plans, Welldoc’s single platform allows users to properly self-manage their chronic conditions regardless of their proximity to providers. 1 https://www.cdc.gov/chronicdisease/ 2 https://www.ncbi.nlm.nih.gov/pmc/articles/ 1 https://www.aamc.org/media/54681/download?attachment 2 https://www.mercer.us/our-thinking/career/demand-for-healthcare-workers-will-outpace-supply-by-2025.html 3 Statista, U.S.: Active doctors number by specialty (2019)

Tech Differentiators

Welldoc operates ahead of the curve of innovation and proactively adapts to market and consumer needs. Our capacity to expand our offerings is based on our understanding of the healthcare ecosystem, specialized expertise in creating digital health in chronic care and a flexible, partnership-based model. Our chronic care platform brings first-in-class clinical, tech, and advanced AI expertise, as demonstrated by Welldoc’s 60+ clinical posters & publications, 31 patents, and 9 510(k) FDA clearances for BlueStar*. Welldoc’s partnerships with health industry leaders, health plans, health systems, employers and partners ensures the company is informed about the needs of all stakeholders, and how their needs will evolve. This foresight enables Welldoc to deliver a best-in-class digital health solution, while ensuring seamless integration into existing health ecosystems. Given our robust regulatory and clinical expertise, we are able to strategically partner with life science and medical device industry leaders to build innovative solutions to further support complex chronic conditions. Welldoc is committed to supporting a positive and engaging user experience. We currently have a ind Net Promoter Score (NPS) of 70.1, indicating high satisfaction across our users. *Welldoc Diabetes Rx/OTC is an FDA-cleared medical device (“BlueStar”), intended for use by healthcare providers and their adult patients with type 1 or type 2 diabetes. For full labeling information, visit www.welldoc.com. The other Welldoc products are non-FDA-cleared and intended to promote general wellness and education/self-management of various chronic disease states.


By leveraging the power of data, AI and clinical science, Welldoc’s single platform provides individuals with real-time, personalized digital coaching to self-manage their health and better coordinate with health care providers in meeting their treatment goals. Welldoc has studied our impact on A1C levels showing a 1.2 to 2.0-point mean A1C reduction in individuals living with type 2 diabetes(1,2). Welldoc has also found that for individuals with blood pressure baselines greater than 130mmHG, an average of 7.2-12 mmHG was observed in the first three months of BlueStar use focused on diabetes management(3), demonstrating the value and our ability in supporting multiple conditions through one holistic solution. We are also leading the way with new innovations, as shown by our continued research on the impact of digital health in combination with real-time innovations like continuous glucose monitoring (CGM). Welldoc partnered with Truven Analytics®/IBM Watson HealthTM to leverage their Market Scan Database to determine the potential impact of A1C reduction to cost outcomes to quantify the economic impact of our solution as users lower their A1C levels. According to this analysis, we are able to estimate an average cost savings of $3,048-$3,252/person with type 2 diabetes, annually(4,1). 1 https://www.frontiersin.org/articles/10.3389/fcdhc.2021.646963/full 2 https://pubmed.ncbi.nlm.nih.gov/24876589/ 3 https://www.welldoc.com/wp-content/ 4 https://acrobat.adobe.com/link/review?uri=urn%3Aaaid%3Ascds%3AUS%3A843eee7c-ef22-4e57-9292-5e61f1ff7bf 0#pageNum=1

Why Us